MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
24.61
+1.34
+5.76%
Pre Market: 24.33 -0.28 -1.14% 07:55 04/09 EDT
OPEN
24.28
PREV CLOSE
23.27
HIGH
24.70
LOW
23.65
VOLUME
11
TURNOVER
0
52 WEEK HIGH
31.77
52 WEEK LOW
11.86
MARKET CAP
3.05B
P/E (TTM)
-193.9322
1D
5D
1M
3M
1Y
5Y
1D
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
The Motley Fool · 1d ago
Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next
Simply Wall St · 1d ago
Palvella Therapeutics names Kent Taylor senior vice president of sales
Reuters · 2d ago
Weekly Report: what happened at ARQT last week (0330-0403)?
Weekly Report · 3d ago
Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million
Reuters · 5d ago
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS
NASDAQ · 6d ago
Assessing Arcutis Biotherapeutics (ARQT) Valuation After Positive ZORYVE Infant Phase 2 Trial Results
Simply Wall St · 04/01 21:24
Arcutis management to present at Needham Virtual Healthcare Conference fireside chat
Reuters · 03/31 20:11
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.